India · Delayed Price · Currency is INR Rossari Biotech Statistics
Total Valuation
Rossari Biotech has a market cap or net worth of INR 23.82 billion. The enterprise value is 26.23 billion.
| Market Cap | 23.82B |
| Enterprise Value | 26.23B |
Important Dates
The last earnings date was Saturday, October 17, 2026.
| Earnings Date | Oct 17, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
Rossari Biotech has 55.39 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 55.39M |
| Shares Outstanding | 55.39M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 53.47% |
| Owned by Institutions (%) | 17.09% |
| Float | 17.65M |
Valuation Ratios
The trailing PE ratio is 15.61 and the forward PE ratio is 14.26. Rossari Biotech's PEG ratio is 1.15.
| PE Ratio | 15.61 |
| Forward PE | 14.26 |
| PS Ratio | 0.89 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.99 |
| P/FCF Ratio | 57.66 |
| P/OCF Ratio | 10.74 |
| PEG Ratio | 1.15 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.77, with an EV/FCF ratio of 63.49.
| EV / Earnings | 17.15 |
| EV / Sales | 0.98 |
| EV / EBITDA | 8.77 |
| EV / EBIT | 13.10 |
| EV / FCF | 63.49 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.62 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.31 |
| Debt / FCF | 9.41 |
| Interest Coverage | 5.44 |
Financial Efficiency
Return on equity (ROE) is 11.49% and return on invested capital (ROIC) is 8.99%.
| Return on Equity (ROE) | 11.49% |
| Return on Assets (ROA) | 5.57% |
| Return on Invested Capital (ROIC) | 8.99% |
| Return on Capital Employed (ROCE) | 12.72% |
| Weighted Average Cost of Capital (WACC) | 7.27% |
| Revenue Per Employee | 45.49M |
| Profits Per Employee | 2.61M |
| Employee Count | 585 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 4.54 |
Taxes
In the past 12 months, Rossari Biotech has paid 509.42 million in taxes.
| Income Tax | 509.42M |
| Effective Tax Rate | 25.01% |
Stock Price Statistics
The stock price has decreased by -31.64% in the last 52 weeks. The beta is 0.56, so Rossari Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -31.64% |
| 50-Day Moving Average | 432.44 |
| 200-Day Moving Average | 484.29 |
| Relative Strength Index (RSI) | 53.43 |
| Average Volume (20 Days) | 81,086 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rossari Biotech had revenue of INR 26.61 billion and earned 1.53 billion in profits. Earnings per share was 27.54.
| Revenue | 26.61B |
| Gross Profit | 7.88B |
| Operating Income | 1.98B |
| Pretax Income | 2.04B |
| Net Income | 1.53B |
| EBITDA | 2.88B |
| EBIT | 1.98B |
| Earnings Per Share (EPS) | 27.54 |
Balance Sheet
The company has 1.47 billion in cash and 3.88 billion in debt, with a net cash position of -2.41 billion or -43.46 per share.
| Cash & Cash Equivalents | 1.47B |
| Total Debt | 3.88B |
| Net Cash | -2.41B |
| Net Cash Per Share | -43.46 |
| Equity (Book Value) | 14.08B |
| Book Value Per Share | 253.97 |
| Working Capital | 4.98B |
Cash Flow
In the last 12 months, operating cash flow was 2.22 billion and capital expenditures -1.80 billion, giving a free cash flow of 412.55 million.
| Operating Cash Flow | 2.22B |
| Capital Expenditures | -1.80B |
| Depreciation & Amortization | 900.31M |
| Net Borrowing | 287.62M |
| Free Cash Flow | 412.55M |
| FCF Per Share | 7.45 |
Margins
Gross margin is 29.61%, with operating and profit margins of 7.44% and 5.74%.
| Gross Margin | 29.61% |
| Operating Margin | 7.44% |
| Pretax Margin | 7.65% |
| Profit Margin | 5.74% |
| EBITDA Margin | 10.82% |
| EBIT Margin | 7.44% |
| FCF Margin | 1.55% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.12%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1.81% |
| FCF Payout Ratio | 6.71% |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.06% |
| Earnings Yield | 6.41% |
| FCF Yield | 1.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Rossari Biotech is 575.50, which is 33.84% higher than the current price. The consensus rating is "Buy".
| Price Target | 575.50 |
| Price Target Difference | 33.84% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 10.53% |
| EPS Growth Forecast (3Y) | 8.50% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |